115 related articles for article (PubMed ID: 3723138)
1. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
3. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
Bystryn JC; Henn M; Li J; Shroba S
Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and tumor protective activity of B16 melanoma vaccines.
Johnston D; Bystryn JC
Mol Biother; 1989; 1(4):218-22. PubMed ID: 2818873
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Reynolds SR; Zeleniuch-Jacquotte A; Shapiro RL; Roses DF; Harris MN; Johnston D; Bystryn JC
Clin Cancer Res; 2003 Feb; 9(2):657-62. PubMed ID: 12576432
[TBL] [Abstract][Full Text] [Related]
7. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
9. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
11. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
[TBL] [Abstract][Full Text] [Related]
12. [Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine].
Takeyama H; Watanabe T; Livingston PO
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1624-33. PubMed ID: 6870307
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
15. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.
Berthier-Vergnes O; Portoukalian J; Lefthériotis E; Doré JF
Cancer Res; 1994 May; 54(9):2433-9. PubMed ID: 8162593
[TBL] [Abstract][Full Text] [Related]
16. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
17. Characterization of polyvalent allogeneic vaccines.
Van Epps D
Dev Biol (Basel); 2004; 116():79-90; discussion 133-43. PubMed ID: 15603185
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of a polyvalent melanoma antigen vaccine.
Bystryn JC
Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302
[TBL] [Abstract][Full Text] [Related]
19. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.
Takeuchi H; Kuo C; Morton DL; Wang HJ; Hoon DS
Cancer Res; 2003 Jan; 63(2):441-8. PubMed ID: 12543800
[TBL] [Abstract][Full Text] [Related]
20. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
